Provide one-year safety and biomarker data for the AMT-130 lower dose cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 May 2022
- Due
- 30 Jun 2022
- Delivered
- 23 Jun 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“One year safety and biomarker data from all 10 patients in lower dose cohort of U.S. Phase I/II study of AMT-130... expected in second quarter 2022”
What we found
Evidence strength A What the grades mean
The company announced 12-month safety and biomarker data for the lower-dose cohort of the U.S. Phase I/II study of AMT-130 on June 23, 2022, meeting the second quarter 2022 deadline.
-
A uniQure N.V. 10-K filed 2023-02-27
“On June 23, 2022, we announced safety and biomarker data from the 10 patients enrolled in the lower-dose cohort. At 12 months of follow-up on the patients in the lower-dose cohort” ✓ confirmed on the page
Market reaction: the shares moved +8.2% against the S&P 500 over the three sessions around the disclosure (24 Feb 2023 to 1 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- AMT-130 clinical data
- Target
- 10 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-QURE-001800 · Corrections policy